Final Diagnosis
Invasive urothelial carcinoma, high-grade (WHO/ISUP), pathologic stage pT4, N2
Discussion
Urothelial carcinoma (UC) is a malignant tumor arising from the urothelial lining. UC can be further subdivided into urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma (UTUC).
UCB is considered invasive once the tumor penetrates the basement membrane and enters the lamina propria or deeper tissues. Conventional urothelial carcinoma demonstrates malignant cells arranged in nests and cords with high grade morphologic features such as loss of cell polarity, nuclear enlargement, marked pleomorphism, dense clumped chromatin, and prominent nucleoli [1]. The 5th edition of the WHO classification outlines numerous histologic variants including micropapillary, nested, plasmacytoid, and sarcomatoid, among others [2]. Tumor stage and depth of invasion are the most important determinants of prognosis [3]. The disease is common, representing the fourth most frequent malignancy in U.S. men, with incidence strongly influenced by age, sex, and race [4].
UCB carcinogenesis is closely linked to environmental exposures, particularly tobacco smoking, which accounts for roughly half of cases [5]. Occupational exposure to aromatic amines and related chemicals also plays a significant role, while genetic predisposition contributes in some patients. Clinically, patients often present with hematuria, dysuria, or urinary frequency. Diagnosis typically relies on cystoscopy with biopsy or transurethral resection, supported by urine cytology and radiologic findings such as bladder wall thickening or mass lesions on CT or MRI [6].
Prognosis of UCB correlates with stage as tumors invading the lamina propria (T1) may be managed conservatively with intravesical therapies like BCG, whereas invasion of the muscularis propria (T2) usually necessitates radical cystectomy [7]. Advanced disease often requires systemic chemotherapy, immunotherapy, or occasionally radiation [7]. The National Comprehensive Cancer Network (NCCN) states that micropapillary, plasmacytoid, small cell/ neuroendocrine and sarcomatoid histologies (in pure or mixed form with associated urothelial carcinoma) are associated with a higher risk for progression, muscle invasive disease and disease recurrence. Therefore, a more aggressive approach should be considered, often with radical cystectomy [8]. For cases of pure small cell carcinoma of the bladder—or mixed tumors containing both small cell and urothelial components—neurologic imaging is recommended. Identifying a small cell component is particularly important, as NCCN guidelines advise treating these patients with concurrent chemoradiotherapy or neoadjuvant systemic therapy followed by local treatment. This approach differs from the standard management of urothelial carcinoma.
Upper tract urothelial carcinomas (UTUC) differ from lower tract urothelial carcinomas in epidemiology, clinical presentation, molecular characteristics, and treatment approaches, despite sharing the same cell of origin. UTUC is significantly rarer, accounting for only 5-10% of all urothelial carcinomas, with the remaining 90-95% occurring in the bladder [9]. UTUC typically presents with more advanced disease with over half of cases demonstrating muscle invasion and approximately one third presenting with metastatic disease at the time of diagnosis [10]. There are many technical limitations that make early detection of upper tract disease difficult to diagnose, and patients remain relatively asymptomatic until further progression. UTUC demonstrates higher frequencies of FGFR3 mutations along with mutations in TP53 and PIK3CA [11]. Studies have noted marked discrepancies in the mutational landscape for urothelial carcinoma, as aristolochic acid exposure (signature 22) is observed in UTUC cohorts, while defective DNA mismatch repair signatures (signature 6) was seen in UCB cohorts [11]. The treatment of UTUC differs from UCB as PD-L1 expression is typically lower in UTUC than in UCB, thus the response to immunotherapy may by lower in UTUC when compared to UCB [11]. Neoadjuvant chemotherapy is particularly important in UTUC as radical nephroureterectomy can result in loss of kidney function that may preclude adjuvant cisplatin-based therapy [12]. The NCCN recommends considering neoadjuvant chemotherapy in selected patients with high-grade UTUC. As previously mentioned, certain histologic variants of UCB confer a worse prognosis and should be reported in order to guide proper therapy. A meta-analysis of variant histology in UTUC demonstrated that the same histologies (micropapillary, plasmacytoid, small cell/neuroendocrine, and sarcomatoid subtypes) are associated with worse outcomes in UTUC and warrant consideration of intensified treatment approaches [13].
Interestingly, there appears to be a strong association with UTUC and Lynch syndrome. After colorectal and endometrial cancers, UTUC is the 3rd most common malignancy in the Lynch syndrome spectrum [14]. The prevalence of Lynch syndrome among UTUC patients ranges from 1-9%, which is comparable to the 2-6% prevalence of Lynch syndrome in both colorectal and endometrial cancers [15]. Therefore, universal screening for Lynch syndrome is recommended for all patients diagnosed with UTUC. According to the NCCN studies, MSH2 mutation carriers face the highest risk for UTUC among Lynch syndrome patients.
Diagnosis of UCB and UTUC may be supplemented by immunohistochemistry, with markers such as GATA3, CK7, CK20, p63, and uroplakins supporting urothelial origin [16]. Additionally, PAX8 is frequently positive in upper tract urothelial carcinoma, and p63 might be of value in resolving the differential diagnosis of UTUC vs RCC. Overall, survival rates vary widely by stage, emphasizing early detection and accurate assessment of invasion.
In conclusion, urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma (UTUC) share many similarities and differences. Both diseases share a similar cell of origin, histology and histologic variants, and immunohistochemical profiles. However there are many differences between UCB and UTUC such as epidemiology, clinical presentation, molecular characteristics, and treatment approaches. Having an understanding of the key similarities and differences is essential to make the distinction between the two entities, as doing so carries significant clinical impact on patient care.
References
[1] McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001 Mar;25(3):356-62. doi: 10.1097/00000478-200103000-00010. PMID: 11224606.
[2] Al-Ahmadie H, Iyer G. Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants. Surg Pathol Clin. 2018 Dec;11(4):713-723. doi: 10.1016/j.path.2018.07.011. Epub 2018 Oct 17. PMID: 30447837; PMCID: PMC6768438.
[3] Solomon JP, Hansel DE. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Adv Anat Pathol. 2015 Mar;22(2):102-12. doi: 10.1097/PAP.0000000000000050. PMID: 25664945.
[4] Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. Journal of Urology [Internet]. 2024 Apr 1 [cited 2025 Dec 17];211(4):533–8. Available from: https://doi.org/10.1097/JU.0000000000003846